8 Best Small Cap Pharma Stocks to Buy Right Now
This article lists the best small-cap pharma stocks, focusing on Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH). It details a recent downgrade by Wells Fargo due to revenue trajectory concerns and issues with a potential interchangeability status for AMP-004. Despite this, the company reported strong Q1 2026 results with progress in commercial base strengthening and pipeline advancements, including a new product launch and an exclusive licensing agreement.
Amphastar Pharmaceuticals Q1 2026: Revenue Miss and Pricing Pressures on BAQSIMI
Amphastar Pharmaceuticals reported flat revenue and missed adjusted profit forecasts in Q1 2026, causing a negative stock response. The company attributed these results to persistent price reductions, particularly for its diabetes treatment BAQSIMI, and increased competition. Analysts inquired about BAQSIMI's pricing challenges, timelines for synthetic corticotropin, insulin aspart biosimilar initiatives, and the market potential for new products, alongside concerns about future glucagon sales.
Pharma Earnings Season 2026: Amphastar Flat, Eli Lilly Surges in Q1 - News and Statistics
The pharmaceutical sector experienced mixed Q1 2026 earnings, with overall revenues exceeding analyst estimates by 1.5% but share prices declining by an average of 4.1%. Amphastar Pharmaceuticals reported flat revenues of $171.2 million, missing expectations and leading to a 25.1% stock drop. In contrast, Eli Lilly saw a significant surge, with revenues increasing 55.5% year-over-year to $19.8 billion, greatly surpassing analyst predictions.
Amphastar Pharmaceuticals' (NASDAQ:AMPH) Conservative Accounting Might Explain Soft Earnings
Amphastar Pharmaceuticals' recent earnings announcement did not impress shareholders, but an analysis suggests that unusual items significantly impacted profit. The company's profit was reduced by US$23 million due to these non-recurring items, implying that future earnings could improve if these expenses do not repeat. This indicates that Amphastar Pharmaceuticals' earnings potential might be better than the recent headline numbers suggest.
There May Be Some Bright Spots In Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings
Amphastar Pharmaceuticals' recent earnings report was disappointing due to soft headline numbers and a significant US$23m expense from unusual items. However, Simply Wall St suggests that these unusual items are often not repeated, potentially leading to higher profits next year. The article advises investors to look beyond the immediate figures and consider the company's underlying earnings potential.
Why Amphastar Pharmaceuticals (AMPH) Stock Is Trading Lower Today
Amphastar Pharmaceuticals (AMPH) stock is trading lower by 2.8% today after Wells Fargo downgraded the company's stock to 'Equalweight' from 'Overweight' and significantly lowered its price target from $30 to $19. This downgrade follows a 19.1% drop in the stock price six days prior due to disappointing first-quarter 2026 financial results, where the company missed profit expectations and reported a substantial decline in earnings. The stock is down 33.3% year-to-date and 42.7% below its 52-week high.
Amphastar Pharmaceuticals Tackles BAQSIMI Discount Pressure, Keeps Sales Outlook
Amphastar Pharmaceuticals is addressing significant "double discounting" pressure on its BAQSIMI product, primarily due to 340B programs, which impacted first-quarter sales. The company
Amphastar forecasts BAQSIMI revenue flat to up low single digits, with 3% list price increase
Amphastar Pharmaceuticals is projecting that revenue from its BAQSIMI product will be flat to slightly up by a low single-digit percentage. This forecast includes a 3% increase in the list price of BAQSIMI. This financial outlook provides insight into the company's expectations for one of its key products.
Amphastar Pharmaceuticals (NASDAQ:AMPH) Earns Neutral Rating from Piper Sandler
Piper Sandler reaffirmed its "neutral" rating on Amphastar Pharmaceuticals (NASDAQ:AMPH) but lowered its price target from $25 to $21, indicating a modest potential upside. This comes after the company reported Q1 earnings of $0.42 per share and revenue of $171.17 million, both missing analyst expectations. Other analysts have also adjusted their ratings and price targets, resulting in a consensus "Hold" rating and an average price target of $26.86 for AMPH.
Amphastar Pharmaceuticals (NASDAQ:AMPH) Posts Quarterly Earnings Results
Amphastar Pharmaceuticals (NASDAQ:AMPH) reported disappointing quarterly earnings, missing analyst expectations with adjusted EPS of $0.42 and revenue of $171.2 million, largely due to a 15% decline in BAQSIMI sales. Despite negative sentiment and a significant drop in stock price, the company saw growth in other products like Primatene MIST and launched a new generic, AMP-007, while maintaining strong financial flexibility through operating cash flow and stock repurchases. Analysts have largely maintained a "Hold" rating on AMPH.
Amphastar Pharmaceuticals, Inc. $AMPH Shares Purchased by Denali Advisors LLC
Denali Advisors LLC significantly increased its stake in Amphastar Pharmaceuticals (NASDAQ:AMPH) during the fourth quarter, purchasing an additional 76,765 shares to own a total of 211,765 shares valued at $5.67 million. This increase in institutional ownership comes despite Amphastar reporting adjusted EPS of $0.42 on revenue of $171.2 million, missing analyst expectations. Analyst sentiment remains cautious, with a consensus "Hold" rating and several firms cutting price targets after the recent earnings miss, though management expects BAQSIMI revenue to remain stable.
Amphastar Pharmaceuticals (AMPH) Is Up 9.4% After Profit Falls Despite New Drug Launches And Licensing Deals
Amphastar Pharmaceuticals (AMPH) reported a 9.4% stock increase despite a significant drop in first-quarter 2026 profits, with net income falling to US$6.42 million and diluted EPS to US$0.14 due to higher costs. This occurred even after the launch of a new inhalation product and a licensing deal. The article highlights concerns about cost pressures impacting profitability and the tension between the company's investment in its pipeline and the immediate financial impact of increased expenses.
Why Amphastar Pharmaceuticals (AMPH) Is Up 9.4% After Profit Squeeze Despite Flat Q1 2026 Sales
Amphastar Pharmaceuticals (AMPH) saw its stock rise by 9.4% despite reporting a sharp drop in net income for Q1 2026, with sales remaining flat. This profit squeeze highlights pressure on the company's profitability and cost structure. Upcoming presentations by management at a healthcare conference will be crucial for explaining these margin issues and reassuring investors about its future financial performance and investment narrative.
Amphastar's CFO and regulatory chief speak May 13; webcast open
Amphastar Pharmaceuticals (NASDAQ: AMPH) announced that its CFO, Bill Peters, and EVP of Regulatory Affairs and Clinical Operations, Tony Marrs, will present at the 2026 Bank of America Health Care Conference on May 13, 2026, at 3:00 pm PT. They will discuss corporate strategy, and a webcast of their presentation will be available on Amphastar's investor website for 30 days. The news of the presentation led to a moderate positive market reaction, with AMPH shares gaining 2.18% on the day of publication.
This HubSpot Analyst Turns Bearish; Here Are Top 5 Downgrades For Friday
This article lists the top five analyst downgrades for Friday, originating from various Wall Street firms. Among the companies downgraded are HubSpot Inc (HUBS), The Trade Desk Inc (TTD), Vital Farms Inc (VITL), Entrada Therapeutics (TRDA), and Amphastar Pharmaceuticals Inc (AMPH). Analysts cited reasons for the downgrades and adjusted price targets for some of these stocks.
Why Amphastar Pharmaceuticals (AMPH) Is Up 9.4% After Profit Squeeze Despite Flat Q1 2026 Sales
Amphastar Pharmaceuticals (AMPH) reported a significant 9.4% rise in its stock price despite a sharp 74.5% drop in net income to US$6.42 million for Q1 2026, even as sales remained flat at US$171.17 million. This profit squeeze highlights pressure on the company's profitability and cost structure. Investors are now keenly awaiting answers from management at an upcoming conference regarding the drivers of weaker margins and the long-term investment case, especially given ambitious revenue and earnings forecasts for 2029.
Amphastar: Q1 Earnings Snapshot
Amphastar Pharmaceuticals Inc. reported first-quarter earnings of $6.4 million, or 14 cents per share, which adjusted to 42 cents per share. This fell short of analyst expectations of 70 cents per share. The company generated $171.2 million in revenue and its shares have dropped 10% year-to-date.
Amphastar: Q1 Earnings Snapshot
Amphastar Pharmaceuticals Inc. reported first-quarter earnings of $6.4 million, or 14 cents per share, which adjusted to 42 cents per share. These results fell below Wall Street's expectations of 70 cents per share from analysts surveyed by Zacks Investment Research. The company's revenue for the period was $171.2 million, and its shares have declined 10% year-to-date.
Amphastar held sales at $171M, but profit fell on higher costs
Amphastar Pharmaceuticals reported Q1 2026 net revenues of $171.2 million, flat year-over-year, but GAAP net income dropped significantly to $6.4 million from $25.3 million in Q1 2025 due to higher costs. The company's gross margin decreased to 41.1% from 50.0%, primarily impacted by lower average selling prices for high-margin products and increased manufacturing and R&D expenses. Despite the profit decline, Amphastar launched a new product and in-licensed another, maintaining an active pipeline with several ANDA and biosimilar filings.
Earnings slide at Amphastar (NASDAQ: AMPH) despite steady Q1 revenue
Amphastar Pharmaceuticals reported flat Q1 2026 revenues at $171.2 million, but GAAP net income significantly dropped to $6.4 million from $25.3 million due to increased costs and narrower gross margins. The company's profitability deterioration was driven by an 18% rise in cost of revenues, higher R&D, and G&A expenses. Despite the earnings slide, Amphastar maintained strong operating cash flow of $47.8 million and continues to advance its product pipeline with new approvals and license agreements.
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026
Amphastar Pharmaceuticals reported its financial results for the first quarter ended March 31, 2026, with net revenues of $171.2 million and GAAP net income of $6.4 million. The company showcased a strengthening commercial foundation, including the launch of Ipratropium Bromide HFA, and significant pipeline advancements, such as an exclusive license agreement for a synthetic corticotropin compound. Despite a decrease in BAQSIMI® and Glucagon sales, other products like albuterol, iron sucrose, and teriparatide contributed to revenue growth, and the company is pursuing several new drug applications and biosimilar candidates.
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026
Amphastar Pharmaceuticals announced its financial results for the first quarter ended March 31, 2026. The company reported net revenues of $171.2 million, GAAP net income of $6.4 million ($0.14 per share), and adjusted non-GAAP net income of $19.5 million ($0.42 per share). The results were influenced by varied product performances, including increased sales in Primatene MIST® and Epinephrine due to higher unit volumes and supplier shortages, alongside decreases in BAQSIMI® and Glucagon sales.
Amphastar: Q1 Earnings Snapshot
Amphastar Pharmaceuticals Inc. reported first-quarter earnings of $6.4 million, or 14 cents per share. This fell short of Wall Street estimates of 70 cents per share, with adjusted earnings at 42 cents per share. The company posted revenue of $171.2 million, and its shares have dropped 10% since the beginning of the year.
Amphastar Pharmaceuticals to Present at the 2026 Bank of America Health Care Conference
Amphastar Pharmaceuticals, Inc. announced that its CFO, Bill Peters, and EVP of Regulatory Affairs, Tony Marrs, will present at the 2026 Bank of America Health Care Conference on May 13, 2026, at 3:00 pm PT. The webcast of the presentation will be available for 30 days on the company's investor relations website. Amphastar is a biopharmaceutical company specializing in generic and proprietary injectable, inhalation, and intranasal products.
Amphastar Pharmaceuticals to Present at the 2026 Bank of America Health Care Conference
Amphastar Pharmaceuticals, Inc. announced that CFO Bill Peters and EVP of Regulatory Affairs and Clinical Operations Tony Marrs will present at the 2026 Bank of America Health Care Conference on May 13, 2026, at 3:00 pm PT. A webcast of the presentation will be available on the company's website for 30 days. Amphastar Pharmaceuticals is a biopharmaceutical company focused on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products.
Amphastar Pharmaceuticals to Present at the 2026 Bank of America Health Care Conference
Amphastar Pharmaceuticals, Inc. announced that CFO Bill Peters and EVP of Regulatory Affairs and Clinical Operations Tony Marrs will present at the 2026 Bank of America Health Care Conference on Wednesday, May 13, 2026, at 3:00 pm PT. A webcast of the presentation will be available on the company's investor relations website for 30 days. Amphastar specializes in developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalable, and intranasal products, also selling active pharmaceutical ingredients.
Amphastar Pharmaceuticals to Present at the 2026 Bank of America Health Care Conference
Amphastar Pharmaceuticals, Inc. announced that CFO Bill Peters and EVP Tony Marrs will present at the 2026 Bank of America Health Care Conference on May 13, 2026. The presentation will be available via webcast on the company's investor relations website for 30 days. Amphastar is a biopharmaceutical company specializing in generic and proprietary injectable, inhalation, and intranasal products, also selling active pharmaceutical ingredients.
Amphastar Pharmaceuticals to Present at the 2026 Bank of America Health Care Conference
Amphastar Pharmaceuticals, Inc. announced that CFO Bill Peters and EVP of Regulatory Affairs and Clinical Operations Tony Marrs will present at the 2026 Bank of America Health Care Conference on Wednesday, May 13, 2026, at 3:00 pm PT. A webcast of the presentation will be available on the company's website for 30 days. Amphastar focuses on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products.
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives Consensus Rating of "Hold" from Brokerages
Amphastar Pharmaceuticals (NASDAQ:AMPH) has received a consensus "Hold" rating from nine brokerage firms, with an average 12-month target price of $27.43. This follows the company's recent quarterly earnings that missed analyst expectations for both EPS and revenue, leading to several price target reductions and one downgrade. Institutional investors hold approximately 65% of the company's stock, and its shares are currently trading around $21.88.
Jefferies Downgrades Amphastar Pharmaceuticals (AMPH), Cites Lack of Meaningful Upside Catalysts
Jefferies downgraded Amphastar Pharmaceuticals (AMPH) to Hold from Buy, lowering its price target due to new launches being less impactful than expected and a lack of significant upside catalysts, despite an inexpensive valuation. The company reported net revenues of $719.9 million and GAAP net income of $98.1 million for the full year ended December 31, 2025. This article also includes promotional material for an AI stock investment, making a strong case for its potential.
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7, 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced it will release its first-quarter 2026 financial results after the market closes on Thursday, May 7, 2026. The company will also host a conference call at 2:00 p.m. Pacific Time on the same day to discuss these results. Investors can access the call via a toll-free number or the company's website, with a webcast replay available within 24 hours.
After-close Q1 results: Amphastar schedules May 7 investor call
Amphastar Pharmaceuticals (NASDAQ: AMPH) announced that it will release its first-quarter 2026 results after market close on May 7, 2026, and will host a conference call on the same day at 2:00 p.m. PT. Investors can access the call via toll-free or international dial-in numbers, or through a webcast on the company's Investors page, with a replay available within 24 hours. The announcement also highlights key financial figures and past company performance, including Q4 2025 revenues and recent FDA approvals.
AMPH Price Today: Amphastar Pharmaceuticals, Inc. Stock Price, Quote & Chart | MEXC
This article provides current stock information for Amphastar Pharmaceuticals, Inc. (AMPH), including its live price, key market data, recent performance, and details on how to buy the stock on MEXC. It also offers a comprehensive FAQ section covering the company's financials, industry classification, and dividend policy.
Amphastar reports FDA approval for teriparatide injection
Amphastar Pharmaceuticals has received FDA approval for its Abbreviated New Drug Application (ANDA) for teriparatide injection. This approval signifies that Amphastar is able to produce and market a generic version compatible with Eli Lilly’s Forteo, used for osteoporosis treatment. The company is now evaluating its launch schedule, highlighting a potential future increase in generic drug availability for this condition.
Boston Trust Walden Corp Reduces Stock Position in Amphastar Pharmaceuticals, Inc. $AMPH
Boston Trust Walden Corp significantly reduced its stake in Amphastar Pharmaceuticals by 7.3% in the fourth quarter, selling 85,841 shares and holding 1,087,266 shares valued at $29.12 million. This move comes as Amphastar Pharmaceuticals missed quarterly earnings expectations, reporting lower EPS and revenue than consensus estimates. Analyst sentiment is mixed to cautious, with a consensus "Hold" rating and several firms trimming their price targets for the company.
Amphastar Pharmaceuticals Downgrade: Stock Falls After Analyst Move - News and Statistics
Amphastar Pharmaceuticals' stock fell after Jefferies downgraded its rating from Buy to Hold, citing a lack of major positive catalysts and smaller-than-anticipated effects from recent product introductions. Despite significant volatility and a current trading price below its September 2025 peak, an investment made five years ago would still be profitable. The downgrade follows a recent upward movement in the stock linked to broader economic improvements and lower energy costs, which typically benefit healthcare companies.
Jefferies downgrades Amphastar Pharmaceuticals (AMPH)
Jefferies has downgraded Amphastar Pharmaceuticals (AMPH). The article does not provide specific details on why the downgrade occurred or any financial implications.
Jefferies downgrades Amphastar Pharmaceuticals (AMPH)
Jefferies has adjusted its rating on Amphastar Pharmaceuticals (AMPH) to a downgrade. The article is very short and contains no additional details beyond this change in rating from Jefferies.
Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock Price Down 7.4% - Time to Sell?
Amphastar Pharmaceuticals (NASDAQ:AMPH) saw its stock price drop 7.4% on Tuesday, trading down to $21.23 with lower than average volume. This decline follows the company missing quarterly earnings and revenue estimates, alongside recent target and rating cuts from several analysts. The consensus rating for AMPH is currently "Hold" with an average price target of $27.43, and institutional investors own approximately 65% of the company's stock.
Amphastar Pharmaceuticals (NASDAQ:AMPH) Earns Hold Rating from Jefferies Financial Group
Jefferies Financial Group has reissued a "Hold" rating for Amphastar Pharmaceuticals (NASDAQ:AMPH), setting a price target of $22.00, which suggests a roughly 4% downside from its current trading price. This reiteration comes despite recent price target trims by other firms like Wells Fargo, Needham, and Barclays, and follows Amphastar missing its latest quarterly earnings and revenue estimates. The company's stock currently trades around $22.92, with institutional investors holding approximately 65% of its shares.
Amphastar Pharmaceuticals Highlights Baqsimi Milestones, Primatene Growth at Needham Conference
Amphastar Pharmaceuticals provided updates on its growth drivers and pipeline at the Needham conference. The company expects Baqsimi sales to hit $175 million this year, triggering a significant milestone payment, despite some pricing pressure. Primatene Mist is projected for high single to low double-digit growth, while Amphastar also plans for new launches, including AMP-007 in early Q2 and key diabetes biosimilars in 2027.
[ARS] Amphastar Pharmaceuticals, Inc. SEC Filing
This article announces an SEC filing of type ARS for Amphastar Pharmaceuticals, Inc. (AMPH) on April 13, 2026. The filing has a low impact and neutral sentiment. The article provides details about the filing, links to the original document, and offers an overview of AMPH's stock data and recent news.
Do options traders know something about Amphastar Pharmaceuticals stock we don't?
The article title, "Do options traders know something about Amphastar Pharmaceuticals stock we don't?", suggests a market analysis focusing on Amphastar Pharmaceuticals (AMPH) and the implications of options trading activity. It hints at exploring whether unusual options market behavior might signal future stock movements or insider knowledge that the general public and other investors are not yet privy to. Without the full article, specific details about the nature of the options activity or the conclusions drawn are not available.
Amphastar Pharmaceuticals to Present at the 25th Annual Needham Healthcare Conference
Amphastar Pharmaceuticals, Inc. announced that its CFO, EVP of Regulatory Affairs and Clinical Operations, and SVP of Corporate Communication will present at the 25th Annual Needham Healthcare Conference on April 14, 2026. The presentation will be webcast live at 11:45 AM ET and available for replay for 30 days on the company's investor relations website. The biopharmaceutical company specializes in developing and commercializing generic and proprietary injectable, inhalation, and intranasal products, along with active pharmaceutical ingredients.
AMPH Financials: Revenue Breakdown, Margins & Competitor Comparison
This article provides a financial overview of Amphastar Pharmaceuticals, Inc (AMPH), detailing its revenue breakdown, profitability margins, and a comparison with competitors. The company's largest revenue contributor is "Other finished pharmaceutical products," and its gross margin stands at 46.79%. A competitive analysis against AKTS and PCRX is also presented.
Amphastar Pharmaceuticals (NASDAQ:AMPH) Price Target Lowered to $23.00 at Barclays
Barclays has lowered its price target for Amphastar Pharmaceuticals (NASDAQ:AMPH) to $23.00 from $30.00, maintaining an "equal weight" rating. This adjustment comes after the company recently missed quarterly earnings and revenue estimates. The new target implies a potential upside of approximately 12% from its previous close, with the stock currently holding an average "Hold" rating from analysts.
Understanding Momentum Shifts in (AMPH)
This article analyzes potential momentum shifts for Amphastar Pharmaceuticals Inc. (AMPH) using AI models. It highlights strong near and mid-term sentiment, a tested support level, and an exceptional risk-reward setup targeting a 20.1% gain. The piece also outlines three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and holding periods, along with multi-timeframe signal analysis.
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Given Average Rating of "Hold" by Brokerages
Amphastar Pharmaceuticals (NASDAQ:AMPH) has received an average "Hold" rating from eight brokerages, with a consensus 1-year target price of $29.50. The company recently missed Q4 earnings estimates, reporting $0.73 EPS against an expected $0.97 and revenue of $183.11 million compared to $190.48 million. Despite institutional investors increasing their holdings, the stock trades with a P/E of 10.14 and has seen several analyst target price reductions.
Amphastar Pharmaceuticals to Present at the 25th Annual Needham Healthcare Conference
Amphastar Pharmaceuticals, Inc. announced that its CFO, EVP of Regulatory Affairs and Clinical Operations, and SVP of Corporate Communication will be presenting at the 25th Annual Needham Healthcare Conference on April 14, 2026. A webcast of the presentation will be available on the company's investor relations website for 30 days following the event. Amphastar Pharmaceuticals focuses on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products.
Amphastar CFO, regulatory chief to present April 14; replay lasts 30 days
Amphastar Pharmaceuticals (NASDAQ: AMPH) will present at the 25th Annual Needham Healthcare Conference on April 14, 2026, at 11:45 am ET. Executives Bill Peters (CFO), Tony Marrs (EVP Regulatory & Clinical), and Dan Dischner (SVP Corporate Communication) will speak. The presentation will be streamed via webcast and available for 30 days on Amphastar's investor website.
